| Castine Dental, Llc | |
|
102 Court Street Castine Community Health Center Castine ME 04421 | |
| (207) 326-9500 | |
| Not Available |
| Full Name | Castine Dental, Llc |
|---|---|
| Speciality | Dentist - General Practice |
| Location | 102 Court Street, Castine, Maine |
| Authorized Official Name and Position | Robert Carl Ciano (DENTIST) |
| Authorized Official Contact | 2073269500 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Castine Dental, Llc Po Box 878 Castine ME 04421-0878 Ph: (207) 326-9500 | Castine Dental, Llc 102 Court Street Castine Community Health Center Castine ME 04421 Ph: (207) 326-9500 |
| NPI Number | 1295937985 |
|---|---|
| Provider Enumeration Date | 06/04/2007 |
| Last Update Date | 08/22/2020 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295937985 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 3581 (Maine) | Primary |
News Archive
Safety in traffic depends on a number of factors. One decisive aspect is how fit the driver is. A research team at the Technische Universitaet Muenchen (TUM), in collaboration with researchers at the BMW Group, managed to develop a sensor system integrated into the steering wheel that can monitor the driver's state of health while driving.
A new Hospital for Special Surgery study suggests that the current rehabilitation used for patients undergoing tendon-bone repairs such as rotator cuff repair may be partially to blame for the high rates of failed healing after surgery. Experiments in a rat model of this injury suggest that immobilizing the limb for four to six weeks after surgery, rather than quickly starting physical therapy, improves healing.
Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,883,872 entitled, Construction of Highly Efficient Cellulase Compositions for Enzymatic Hydrolysis of Cellulose, by the United States Patent and Trademark Office ("USPTO").
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
› Verified 5 days ago